Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: Current status of knowledge and research priorities

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 70-77

  Nachega, Jean B ^a,b   Mills, Edward J ^c   Schechter, Mauro ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adherence; Combination antiretroviral therapy; HIV AIDS; Low income and middle income countries; Retention

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; POVERTY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 74349116997     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328333ad61     Document Type: Review

References (84)

1. Kovacs JA,MasurH.Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.NEngl JMed2000;342:1416-1429. (Pubitemid 30262400)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
4. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
5. Scaling up access to antiretroviral therapy in low and middle-income countries: global and regional progress in 2008. Geneva: UNAIDS-WHO; 2009.
6. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
8. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
9. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
10. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir/ ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45:4-8.
11. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-1268.
12. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and nonnucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
13. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
14. Bangsberg DR, Perry S, Charlebois ED, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
15. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
16. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43:78-84.
17. Wood E, Hogg RS, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts or =200 cells/ ml. AIDS 2006; 20:1117-1123.
18. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690.
19. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369-1375.
20. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004; 20:1053-1056.
21. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav 2009; 13 (Suppl 1):82-91.
22. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 19:1243-1249.
23. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
24. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004; 36:967-971.
25. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438; doi:10.1371/journal.pmed. 0030438.
26. Nachega JB, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep 2009; 6:121-129.
27. Friedland GH. HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1):S3-S9.
28. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1):S149-S155.
29. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5:e109.
30. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008; 197:S272-S278.
31. Nachega JB, Chaisson RE, Goliath RE, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy in HIV-infected adults. In 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8-11 February 2009; Palais de Congres, Montreal, Canada. Abstract #143.
32. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
33. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003; 34:281-288.
34. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 17 (Suppl 3): S103-108.
35. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1):S127-S133.
36. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS 2002; 16:527-535.
37. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med 2001; 110:664-666.
38. Babudieri S, Aceti A, D'Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000; 284:179-180.
39. Fischl M, Rodriguez A, Scerpella E, Monroig R. Impact of directly observed therapy on outcomes in HIV clinical trials. In 7th Retrovirus Conference on Retroviruses and Opportunistic Infection; 31 January to 4 February 2000; San Francisco, CA. Abstract #71. http://www.retroconference.org/2000/ Abstracts/71.htm. (Accessed 19 September 2009)
40. Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12:305-307; 312-316
41. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42:1628-1635.
42. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006; 42:1619-1627.
43. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007; 21:1473-1477.
44. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45:770-778.
45. Gross R, Tierney C, Andrade A, et al., AIDS Clinical Trials Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with selfadministered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med 2009; 169:1224-1232.
46. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Org 2001; 79:1145-1151.
47. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resourcelimited setting. J Acquir Immune Defic Syndr 2004; 36:929-934.
48. Idoko JA, Agbaji O, Agaba P, et al. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS 2007; 18:760-763.
49. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peerdelivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007; 46:238-244.
50. Taiwo B, Idoko JA. Directly observed community-based treatment in Nigeria. New Jersey: IAPAC; 2008.
51. Sarna A, Luchters S, Geibel S, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombassa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 2008; 48:611-619.
52. Bussmann H, Wester CW, Thomas A, et al. Response to zidovudine/ didanosine- containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009; 51:37-46.
53. Gandhi NR, Moll AP, Lalloo U, et al., Tugela Ferry Care and Research (TFCaRes) Collaboration. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009; 50:37-43.
54. Clarke M, Dick J, Zwarenstein M, et al. Lay health worker intervention with choice of DOT superior to standard TB care for farm dwellers in South Africa: a cluster randomized control trial. Int J Tuberc Lung Dis 2005; 9:673-679.
55. Manders AJ, Banerjee A, Van Den Borne HW, et al. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase. Int J Tuberc Lung Dis 2001; 9:838-842.
56. Wilkinson D, Davies GR, Connolly C. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am J Public Health 1996; 86:1094-1097.
57. Newell JN, Baral SC, Pande SB, et al. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367:903-909.
58. Ford N, Nachega JB, Engel M, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomized controlled trials. Lancet (in press).
59. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 2006; 41:285-297.
60. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub- Saharan Africa: an ethnographic study. PLoS Med 2009; 6:e11.
61. Uchino B. Social support and health: a review of physiologic processes potentially underlying links to disease outcomes. J Behav Med 2006; 29:377-387.
62. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2006:CD00144.
63. Petersen ML,Wang Y, Van Der Laan MJ, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 2007; 45:908-915.
64. Puccio JA, Belzer M, Olson J, et al. The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. AIDS Patient Care STDS 2006; 20:438-444.
65. Donald S, Ulrike R, Charissa B, Skinner D. Evaluation of use of cell phones to aid compliance with drug therapy for HIV patients. AIDS Care 2007; 19:605-607.
66. Green D. South Africa: a novel approach to improving adherence to TB treatment. Essent Drugs Monit 2003; 33:8. http://mednet2.who.int/ edmonitor/33/EDM33-8-TB-e.pdf. (Accessed 17 September 2007)
67. Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials 2009; 10:87.
68. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers and a mobile phone support intervention on AIDS care in Rakai, Uganda: a clusterrandomized trial. IAS Meeting; 19-22 July 2009; Cape Town. Abstract #WEPED158. http://www.ias2009.org/pag/Abstracts.aspx?AID=129. (Accessed 7 September 2009)
69. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119:e1371-e1383.
70. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009; 51:65-71.
71. Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav 2006; 10:S85-S93.
72. Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, et al. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr 2007; 27:123-131.
73. Davies MA, Boulle A, Fakir T, et al. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr 2008; 8:34.
74. Freedberg KA, Hirschorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIVinfected patients. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1): S113-118.
75. Nachega JB, Leisegang R, Bishai D, et al. Effect of adherence to NNRTIbased ART on healthcare costs in a private sector HIV/AIDS management program in southern Africa. Ann Intern Med (in press).
76. Ellman T, Culbert H, Torres-Feced V. Treatment of AIDS in conflict-affected settings: a failure of imagination. Lancet 2005; 365:278-280.
77. Culbert H, Tu D, O'Brien DP, et al. HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med 2007; 4:e129.
78. Kiboneka A, Nyatia RJ, Nabiryo C, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ 2009; 338:b201.
79. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
80. Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135-139.
81. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pretreatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9:290.
82. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009; 14:1048-1058.
83. Brinkhof MG, Dabis F, Myer L, et al., for the ART-LINC of IeDEA Collaboration Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Org 2008; 86.
84. Van Cutsem G, Hilderbrand K, Mathee S, et al. Loss to follow-up and associated factors at different durations of antiretroviral therapy in Khayelitsha, South Africa. IAS Meeting; 19-22 July 2009; Cape Town. Abstract #WEPEB284. http://www.ias2009.org/pag/Abstracts.aspx?AID=2882. (Accessed 7 September 2009)